EDIT

Healthcare Biotechnology

Editas Medicine, Inc.

$2.62

+0.05 +1.95% today

Price History

Not enough data

Key Stats

Market Cap

402.38M

Avg Volume

2.47M

EPS

-$0.66

52W High

$4.54

52W Low

$1.66

Div. Yield

0.0%

Analyst Ratings

Hold

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-3.48

P/B Ratio

3.82

P/S Ratio

8.56

EV/EBITDA

-2.54

EV/Revenue

4.39

Margins

Gross Margin (80.7%)

Operating Margin (167.3%)

Net Margin (157.3%)

EBITDA Margin (172.4%)

Growth & Returns

Revenue Growth (YoY)

232.3%

Return on Equity

(118.8%)

Return on Assets

(23.3%)

Liquidity & Leverage

Current Ratio

3.19

Quick Ratio

3.13

Debt / Equity

0.15

Total Cash

211.64M

Total Debt

15.51M

About

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.